Anti-canine CD20 antibody
Isolated canine antibodies with specific CDR sequences, produced in transgenic rodents, address the lack of effective therapies for canine CD20 by providing targeted treatment for B-cell lymphoma and other conditions with enhanced efficacy and reduced immunogenicity.
JP7873686B2Inactive Publication Date: 2026-06-12ZOETIS SERVICES UK LTD
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- ZOETIS SERVICES UK LTD
- Filing Date
- 2022-06-17
- Publication Date
- 2026-06-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
⚠Technical Problem
There is a need for effective therapies targeting canine CD20, as existing human antibodies like rituximab are not currently in common clinical use for treating canine lymphoma and other B-cell mediated conditions.
⚗Method used
Development of isolated canine antibodies or their antigen-binding moieties that specifically bind to canine CD20, utilizing specific CDR sequences and variable regions, produced in transgenic rodents to minimize immunogenicity and ensure optimal affinity and efficacy.
🎯Benefits of technology
The canine antibodies effectively target CD20-expressing cells, offering potential therapeutic benefits for B-cell lymphoma and other B-cell mediated conditions in dogs, with reduced risk of immunogenicity and improved affinity.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 0007873686000042 
Figure 0007873686000043 
Figure 0007873686000044
Abstract
The present disclosure relates to antibodies and antigen-binding portions thereof that bind to canine CD20. The present disclosure also relates to compositions and methods for the treatment of B-cell mediated conditions in canine subjects.
Need to check novelty before this filing date? Find Prior Art